Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,144
  • Shares Outstanding, K 89,936
  • Annual Sales, $ 320 K
  • Annual Income, $ -82,100 K
  • EBIT $ -93 M
  • EBITDA $ -100 M
  • 60-Month Beta 1.13
  • Price/Sales 244.27
  • Price/Cash Flow N/A
  • Price/Book 0.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.26 on 11/07/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 95.38% ( -51.76%)
  • Historical Volatility 54.85%
  • IV Percentile 77%
  • IV Rank 15.85%
  • IV High 532.16% on 11/15/24
  • IV Low 13.11% on 12/12/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 10,274
  • Open Int (30-Day) 11,511

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.26
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.31
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8300 +6.02%
on 11/15/24
1.1200 -21.43%
on 11/08/24
-0.0010 (-0.11%)
since 10/18/24
3-Month
0.8000 +10.00%
on 10/15/24
1.1600 -24.14%
on 08/21/24
-0.1800 (-16.98%)
since 08/20/24
52-Week
0.7500 +17.33%
on 08/13/24
1.3000 -32.31%
on 03/08/24
-0.1200 (-12.00%)
since 11/20/23

Most Recent Stories

More News
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

CMRX : 0.8800 (unch)
Chimerix: Q3 Earnings Snapshot

Chimerix: Q3 Earnings Snapshot

CMRX : 0.8800 (unch)
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

CMRX : 0.8800 (unch)
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

CMRX : 0.8800 (unch)
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CMRX : 0.8800 (unch)
Chimerix: Q2 Earnings Snapshot

Chimerix: Q2 Earnings Snapshot

CMRX : 0.8800 (unch)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END

BCRX : 7.30 (+1.25%)
NNVC : 1.3300 (-2.92%)
VERU : 0.6253 (-0.30%)
CMRX : 0.8800 (unch)
SIGA : 6.25 (-0.16%)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

NNVC : 1.3300 (-2.92%)
VERU : 0.6253 (-0.30%)
CMRX : 0.8800 (unch)
SIGA : 6.25 (-0.16%)
Chimerix: Q1 Earnings Snapshot

Chimerix: Q1 Earnings Snapshot

CMRX : 0.8800 (unch)
Chimerix: Q4 Earnings Snapshot

Chimerix: Q4 Earnings Snapshot

CMRX : 0.8800 (unch)

Business Summary

Chimerix is a biopharmaceutical company which develop medicines for lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program ONC201, is in development for H3 K27M-mutant glioma. Chimerix is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 0.9333
2nd Resistance Point 0.9167
1st Resistance Point 0.8983
Last Price 0.8800
1st Support Level 0.8633
2nd Support Level 0.8467
3rd Support Level 0.8283

See More

52-Week High 1.3000
Fibonacci 61.8% 1.0899
Fibonacci 50% 1.0250
Fibonacci 38.2% 0.9601
Last Price 0.8800
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar